Variables associated with remission by univariable analyses.
| Characteristic | Remission During Followup | ||
|---|---|---|---|
| Yes (n = 196), n (%) or median (25th–75th percentiles) | No (n = 706), n (%) or median (25th–75th percentiles) | p | |
| Sociodemographic | |||
| Sex | 0.4454 | ||
| Male | 18 (9.2) | 75 (10.6) | |
| Female | 178 (90.8) | 631 (89.4) | |
| Age at diagnosis, yrs | 28, 21–39 | 26, 20–35 | 0.0809 |
| Age at first symptom, yrs | 27, 19–37 | 25, 19–34 | 0.1806 |
| Age at entry, yrs | 28, 21–40 | 26, 20–35 | 0.0644 |
| Race or ethnic group | 0.9977 | ||
| White | 86 (43.9) | 282 (40.1) | |
| Mestizo | 80 (40.8) | 298 (42.4) | |
| African Latin American | 25 (12.8) | 96 (13.7) | |
| Other | 5 (2.6) | 27 (3.8) | |
| Socioeconomic status | 0.0030 | ||
| High/middle high | 27 (13.9) | 54 (7.7) | |
| Middle | 63 (32.5) | 190 (27.0) | |
| Middle low/low | 104 (53.6) | 461 (65.4) | |
| Residence | 0.0605 | ||
| Urban | 185 (94.9) | 632 (90.0) | |
| Rural | 10 (5.1) | 70 (10.0) | |
| Medical coverage | 0.0676 | ||
| None | 17 (8.7) | 118 (16.8) | |
| Partial | 55 (28.2) | 172 (24.5) | |
| Full | 123 (63.1) | 413 (58.7) | |
| Education, yrs | 0.0095 | ||
| 0–7 | 50 (25.9) | 214 (31.8) | |
| 8–12 | 87 (45.1) | 313 (46.5) | |
| ≥ 13 | 56 (29.0) | 146 (21.7) | |
| Disease duration at entry, mos | 0.1454 | ||
| Entered at diagnosis | 107 (54.6) | 438 (62.0) | |
| Up to 6 | 24 (12.2) | 108 (15.3) | |
| 6 to 12 | 26 (13.3) | 75 (10.6) | |
| 13 to 24 | 39 (19.9) | 85 (12.0) | |
| Clinical characteristics at entry | |||
| General manifestations | 135 (68.9) | 517 (73.2) | 0.0742 |
| Musculoskeletal | 183 (93.4) | 630 (89.2) | 0.5158 |
| Mucocutaneous | 165 (84.2) | 635 (89.9) | 0.0490 |
| Ocular | 21 (10.7) | 61 (8.6) | 0.6735 |
| Lung | 7 (3.6) | 33 (4.7) | 0.3088 |
| Cardiovascular | 60 (30.6) | 238 (33.7) | 0.5569 |
| Renal | 68 (34.7) | 330 (46.7) | 0.0085 |
| Neurological | 35 (17.9) | 146 (20.7) | 0.4796 |
| Hematological | 122 (62.2) | 487 (69.0) | 0.0655 |
| Immunological | 123/157 (78.3) | 460/568 (81.0) | 0.3216 |
| Treatments at entry | |||
| Antimalarials | 69 (35.2) | 210 (29.7) | 0.3478 |
| Prednisone (higher dose before baseline) | 0.1604 | ||
| None | 86 (43.9) | 341 (48.3) | |
| Low (≤ 7.5 mg/day) | 5 (2.6) | 11 (1.6) | |
| Medium (> 7.5 ≤ 15 mg/day) | 21 (10.7) | 62 (8.8) | |
| High (> 15 < 60 mg/day) | 50 (25.5) | 206 (29.2) | |
| Very high (≥ 60 mg/day) | 34 (17.3) | 86 (12.2) | |
| Immunosuppressive drugs | 46 (23.5) | 120 (17.0) | 0.1139 |
| Disease status (SLEDAI) at entry | 8, 5–13 | 10, 6–17 | 0.0002 |
Data are n (%) or median, 25th–75th percentiles. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.